• Cochlear confirms it can rely on duty-free importation for hearing implants
• Cochlear will continue to monitor and engage in the evolving global landscape
• Cochlear aims to provide implantable hearing solutions to as many people as possible

Cochlear Limited (ASX:COH) has released a statement in response to the announcement by the US Government on 2 April 2025 regarding the introduction of a 10% tariff on exports to the US from Australia. Cochlear confirms that it will continue to be able to rely on a chapter of the Harmonized Tariff Schedule of the United States that provides for duty-free importation on a range of products into the US, including hearing implants. This means Cochlear will be able to continue providing its implantable hearing solutions to the US market without being impacted by the new tariff. Cochlear will continue to actively monitor and engage in the evolving global landscape so that it can continue to provide these solutions to as many people as possible, and service existing recipients over the course of their life. The company remains committed to ensuring access to its hearing implant technology for people around the world.